These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 19114129)

  • 1. Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications.
    Mimeault M; Batra SK
    Ageing Res Rev; 2009 Apr; 8(2):94-112. PubMed ID: 19114129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aging of tissue-resident adult stem/progenitor cells and their pathological consequences.
    Mimeault M; Batra SK
    Panminerva Med; 2009 Jun; 51(2):57-79. PubMed ID: 19776709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances on skin-resident stem/progenitor cell functions in skin regeneration, aging and cancers and novel anti-aging and cancer therapies.
    Mimeault M; Batra SK
    J Cell Mol Med; 2010 Jan; 14(1-2):116-34. PubMed ID: 19725922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.
    Mimeault M; Batra SK
    Panminerva Med; 2008 Mar; 50(1):3-18. PubMed ID: 18427384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Great promise of tissue-resident adult stem/progenitor cells in transplantation and cancer therapies.
    Mimeault M; Batra SK
    Adv Exp Med Biol; 2012; 741():171-86. PubMed ID: 22457110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem cells and aberrant signaling of molecular systems in skin aging.
    Peng Y; Xuan M; Leung VY; Cheng B
    Ageing Res Rev; 2015 Jan; 19():8-21. PubMed ID: 25446806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.
    Mimeault M; Batra SK
    Gut; 2008 Oct; 57(10):1456-68. PubMed ID: 18791122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stem cells use distinct self-renewal programs at different ages.
    Levi BP; Morrison SJ
    Cold Spring Harb Symp Quant Biol; 2008; 73():539-53. PubMed ID: 19150957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence.
    Mimeault M; Batra SK
    Histol Histopathol; 2010 Aug; 25(8):1057-73. PubMed ID: 20552555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer and aging: the molecular pathways.
    Bassi P; Sacco E
    Urol Oncol; 2009; 27(6):620-7. PubMed ID: 19879472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress on tissue-resident adult stem cell biology and their therapeutic implications.
    Mimeault M; Batra SK
    Stem Cell Rev; 2008; 4(1):27-49. PubMed ID: 18288619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase reverse transcriptase protects ATM-deficient hematopoietic stem cells from ROS-induced apoptosis through a telomere-independent mechanism.
    Nitta E; Yamashita M; Hosokawa K; Xian M; Takubo K; Arai F; Nakada S; Suda T
    Blood; 2011 Apr; 117(16):4169-80. PubMed ID: 21297001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of p53 renders ATM-deficient mice refractory to hepatocarcinogenesis.
    Teoh N; Pyakurel P; Dan YY; Swisshelm K; Hou J; Mitchell C; Fausto N; Gu Y; Farrell G
    Gastroenterology; 2010 Mar; 138(3):1155-65.e1-2. PubMed ID: 19919837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomere dysfunction and cell cycle checkpoints in hematopoietic stem cell aging.
    Ju Z; Zhang J; Gao Y; Cheng T
    Int J Hematol; 2011 Jul; 94(1):33-43. PubMed ID: 21671044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue formation and tissue engineering through host cell recruitment or a potential injectable cell-based biocomposite with replicative potential: Molecular mechanisms controlling cellular senescence and the involvement of controlled transient telomerase activation therapies.
    Babizhayev MA; Yegorov YE
    J Biomed Mater Res A; 2015 Dec; 103(12):3993-4023. PubMed ID: 26034007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanism of hematopoietic stem/progenitor cell aging induced by radiation damage].
    Zhang C; Sun K; Geng S; Liu D; Zhang X; Liu J; Xu C; Wang J; Wang Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Mar; 29(3):233-6. PubMed ID: 23643076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.
    Sharpless NE; Ramsey MR; Balasubramanian P; Castrillon DH; DePinho RA
    Oncogene; 2004 Jan; 23(2):379-85. PubMed ID: 14724566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro aging of rat lung cells. Downregulation of telomerase activity and continuous decrease of telomere length are not incompatible with malignant transformation.
    Petitot F; Lebeau J; Dano L; Lectard B; Altmeyer S; Levalois C; Chevillard S
    Exp Cell Res; 2003 May; 286(1):30-9. PubMed ID: 12729792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomere length maintenance in aging and carcinogenesis.
    Aragona M; Maisano R; Panetta S; Giudice A; Morelli M; La Torre I; La Torre F
    Int J Oncol; 2000 Nov; 17(5):981-9. PubMed ID: 11029502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence.
    Shin J; Yang J; Lee JC; Baek KH
    Cell Signal; 2013 Dec; 25(12):2540-7. PubMed ID: 23993963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.